PDE4-IN-13

• Description :

  PDE4-IN-13 is a PDE4 inhibitor with an IC50 of 1.56 μM. PDE4-IN-13 shows anti-inflammatory and antioxidant properties, and can be used for chronic obstructive pulmonary disease (COPD) research[1].

• UNSPSC :

  12352005

• Target :

  Phosphodiesterase (PDE)

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/pde4-in-13.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(C1=CC=C(O)C(O)=C1)/C=C/C2=CC=C(OC)C(OCC3CC3)=C2

• Molecular Formula :

  C20H20O5

• Molecular Weight :

  340.37

• References & Citations :

  [1]Youzhi Wang, et al. Design and synthesis of a novel class of PDE4 inhibitors with antioxidant properties as bifunctional agents for the potential treatment of COPD. Eur J Med Chem. 2023 Aug 5;256:115374.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PDE4